COMMUNIQUÉS West-GlobeNewswire

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

23/01/2025 - 14:00

Oral presentation at 2025 ASCO Gastrointestinal Cancers Symposium today highlights e vorpacept as the first CD47 blocker to show substantial tumor response and a well-tolerated safety profile in a prospective randomized [...]

ORYZON announces first patient dosed in an Investigator-initiated Phase I study of iadademstat in myelodysplastic syndrome

23/01/2025 - 14:00

Exploring the combination with azacitidine Study led by Medical College of Wisconsin MADRID and CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage [...]

Conduit Pharmaceuticals Inc. Announces Reverse Stock Split

23/01/2025 - 14:00

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a multi-asset, clinical stage, disease-agnostic life science company [...]

Spur Therapeutics Announces Platform and Poster Presentations Highlighting New Clinical Data for FLT201 in Gaucher Disease at Upcoming WORLDSymposium

23/01/2025 - 14:00

LONDON, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced that it will share updated clinical data from its Phase 1/2 GALILEO-1 trial of FLT201, its adeno-associated virus (AAV) gene therapy candidate [...]

MBX Biosciences to Participate in Upcoming February Investor Conferences

23/01/2025 - 14:00

CARMEL, Ind., Jan. 23, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the [...]

Lisata Therapeutics and WARPNINE Announce Encouraging Preliminary Results from the Phase 1b/2a iLSTA Trial Evaluating Certepetide in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma

23/01/2025 - 14:00

Data corroborate previously reported preclinical data demonstrating certepetide’s ability to enhance the effectiveness of immunotherapy Preliminary results to be presented at the 2025 ASCO Gastrointestinal Cancers [...]

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

23/01/2025 - 13:30

Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE [...]

InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference

23/01/2025 - 13:30

JENA, Germany, Jan. 23, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will [...]

BioPorto announces the publication of urinary NGAL reference ranges in healthy adult and pediatric individuals

23/01/2025 - 13:23

News Release January 23, 2025 BioPorto announces the publication of urinary NGAL reference ranges in healthy adult and pediatric individuals COPENHAGEN, DENMARK, January 23, 2025 (GLOBE NEWSWIRE) – BioPorto, an in vitro [...]

Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition

23/01/2025 - 13:15

Private placement of $6.5 million with a global investor and entrepreneur, Mr. Alejandro Weinstein, who will join Pluri’s Board of Directors Pluri to purchase approximately 71% of Kokomodo Ltd.’s shares, a leading [...]

STERIS to Host a Conference Call for Fiscal 2025 Third Quarter Financial Results on February 6, 2025

22/01/2025 - 22:30

DUBLIN, IRELAND , Jan. 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2025 third quarter financial results at 9: [...]

Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab

22/01/2025 - 22:05

NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]

Inotiv, Inc. to Report Fiscal 2025 First Quarter Financial Results and Host Conference Call on Wednesday, February 5, 2025

22/01/2025 - 22:05

WEST LAFAYETTE, Ind., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and [...]

Bionano Announces Effective Date of Reverse Stock Split

22/01/2025 - 22:05

SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO)(the “Company”) today announced that it will effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for [...]

Avid Reminds Stockholders to Vote Today FOR the Transaction with GHO and Ampersand

22/01/2025 - 22:05

Mails Letter to Stockholders Highlighting the Significant, Immediate and Certain Cash Value the Transaction Delivers to Stockholders TUSTIN, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO [...]

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

22/01/2025 - 22:05

SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical [...]

Nusano to Present at Piper Sandler Next-Gen RadioPharma Symposium

22/01/2025 - 22:01

VALENCIA, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of radioisotopes, today announced the company’s CEO Chris Lowe will present at Piper Sandler’s Next-Gen [...]

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

22/01/2025 - 22:01

SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings, Inc. (“ALX Oncology” or the “Company”), (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the [...]

Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025

22/01/2025 - 22:00

Daix (France), New York City (New York, United States), January 22, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development [...]